Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.75 |
| ▸ | PLK1 | P53350 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.54 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406212 | 1.00 | PTPN1 (0.75) | PTPN1PLK1KMT2APOLBTSHR | |
| SCHEMBL23943618 | 0.91 | KMT2A (0.68) | PTPN1KMT2APOLBTSHRLMNA | |
| SCHEMBL7820773 | 0.85 | KMT2A (0.71) | KMT2APOLBTSHRMEN1MAPT | |
| SCHEMBL7697157 | 0.84 | PTPN1 (0.63) | PTPN1PLK1KMT2AMEN1NR1I2 | |
| SCHEMBL18141371 | 0.82 | KMT2A (0.74) | PTPN1KMT2ATSHRMEN1NR1I2 | |
| SCHEMBL112985 | 0.82 | KMT2A (0.74) | PTPN1KMT2ATSHRMEN1NR1I2 | |
| SCHEMBL168816 | 0.82 | KMT2A (0.74) | PTPN1KMT2ATSHRMEN1NR1I2 | |
| SCHEMBL527254 | 0.82 | KMT2A (0.74) | PTPN1KMT2ATSHRMEN1NR1I2 | |
| SCHEMBL1274781 | 0.82 | KMT2A (0.74) | PTPN1KMT2ATSHRMEN1NR1I2 | |
| SCHEMBL2044840 | 0.82 | KMT2A (0.74) | PTPN1KMT2ATSHRMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | claimed |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | LINK THERAPEUTICS, LLC | 2025-10-07 | — | — | US | disclosed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | INSR, IRS1, INSRR | PTPN1 1498/4885PLK1 2223/4885KMT2A 3992/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | PTPN1 1137/4885PLK1 2121/4885KMT2A 4104/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | PTPN1 1498/4885PLK1 2223/4885KMT2A 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.